BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has completed its review of the Company’s listing application and approved the Company’s common stock for listing on The Nasdaq Capital Market. The Company’s common stock is expected to begin trading on Nasdaq on August 7, 2026 under the ticker symbol "BSEM."